Events - Industry Webinar: Diagnosis, Management, and Treatment of IgA Nephropathy in 2023 and Beyond

IgA nephropathy is the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and kidney failure. There is an unmet need in the therapeutic landscape for safe, efficacious drugs for patients at high risk of disease progression. A significant number of patients remain above guideline-recommended proteinuria targets despite optimized supportive care. This webinar will give an overview of current management strategies for IgA nephropathy, showcasing recently approved and pipeline therapeutics to offer a deeper awareness of the evolving treatment landscape.

Learning objectives: 

• Describe the current diagnostic, management, and treatment recommendations outlined in the KDIGO Guidelines
• Highlight the unmet need with current guideline-recommended treatments
• Educate on the burden of disease for IgA nephropathy, the patient journey, and the importance of lowering proteinuria
• Educate on the current treatment landscape for IgA nephropathy and how it is evolving with the introduction of newly approved and pipeline treatments

Further reading: 

• IgA Nephropathy Disease Pathophysiology: Focus on Endothelin-I and Angiotensin II
• The Importance of Proteinuria Reduction in IgA Nephropathy

*This is an industry webinar with content provided by Travere Therapeutics and not the ISN.